Global Diabetes Drugs Market Insights and Forecast to 2028

Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.
Market Analysis and Insights: Global Diabetes Drugs Market
Due to the COVID-19 pandemic, the global Diabetes Drugs market size is estimated to be worth US$ 56710 million in 2022 and is forecast to a readjusted size of US$ 78200 million by 2028 with a CAGR of 5.5% during the review period. Fully considering the economic change by this health crisis, Insulin accounting for % of the Diabetes Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Type 1 Diabetes segment is altered to an % CAGR throughout this forecast period.
Global Diabetes Drugs key players include Novo Nordisk, Sanofi, Eli Lilly, Merck & Co, Boehringer Ingelheim, etc. Global top five manufacturers hold a share over 80%.
North America is the largest market, with a share over 50%, followed by Europe and China, both have a share over 30%.
In terms of product, Insulin is the largest segment, with a share over 45%. And in terms of application, the largest application is Type 1 Diabetes, followed by Type 2.
Global Diabetes Drugs Scope and Segment
Diabetes Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Diabetes Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Insulin
DPP-4
GLP-1
SGLT-2
Segment by Application
Type 1 Diabetes
Type 2 Diabetes
By Company
Sanofi
AstraZeneca
Bayer
Biocon
Boehringer Ingelheim
Dongbao Pharmaceutical
Eli Lilly
Ganlee
Ginwa
Guangzhou Baiyun Mountain
Hisun Pharmacy
Hua Dong
Huadong Medicine
Jumpcan Pharmacy
KELUN
Merck & Co.
MSD
North China Pharmaceutical Group Corporation
Novartis
Novo Nordisk
Sanofi
SHIJIAZHUANG YILING PHARMACEUTICAL
Takeda
Taloph
Tianan Pharmaceutical
Tonghua DongBao
Wanbang Biopharmaceuticals
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Frequently Asked Questions